The global cancer immunotherapy market was valued at more than US$ 92.11 billion in 2024. It is anticipated to increase at a CAGR of 12.84% between 2024 and 2031. The worldwide cancer immunotherapy ...

Co. Ltd. has divulged compounds acting as histone deacetylase 1 (HDAC1) and/or 2 (HDAC2) inhibitors reported to be useful for the treatment of cancer.

HDAC, CDK4/6 inhibitors, DNA damage repair inhibitors, and immunotherapy with ICIs is mechanistically reliable and has some application prospects. In summary, the above inhibitor-targeted therapies ...

1Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China. 2Key Laboratory of Xiamen for Diagnosis ...

In the phase 1b/2 trial, investigators assessed the combination of HBI 8000 with nivolumab for the treatment of patients with advanced melanoma, kidney cancer, and non–small cell lung cancer ...

People with cancer now have a multitude of treatment options beyond chemotherapy and radiation. One such advanced approach, called immune checkpoint inhibitor therapy, enables immune cells called T ...

The phase 3 trial found adding the TIGIT candidate tiragolumab to Roche's approved checkpoint inhibitor had no effect on overall survival (OS) in non-small cell lung cancer (NSCLC). Investigators ...

"Immune checkpoint inhibitor therapies have revolutionized cancer treatment by allowing T cells to attack tumors and cancer cells more effectively. But this hasn't been without side effects—one ...

Subsequently, rucaparib, niraparib, talazoparib, and other PARP inhibitors were successively approved for marketing, with their indications constantly expanding from ovarian cancer to other cancer ...

Belinostat is another HDAC inhibitor approved to treat peripheral ... only small molecule therapeutic targeting these mutations in cancer patients, but the study is a small one, enrolling just ...